MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
15 août 2023 16h03 HE
|
MediWound Ltd.
EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing...
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
15 août 2023 16h02 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
15 août 2023 16h01 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound to Report Second Quarter 2023 Financial Results
07 août 2023 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound Announces Commercial Launch of NexoBrid® in Japan
01 août 2023 07h30 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
10 juil. 2023 07h30 HE
|
MediWound Ltd.
MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd....
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
03 juil. 2023 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, July 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
14 juin 2023 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
30 mai 2023 07h00 HE
|
MediWound Ltd.
On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through profitability ...
MediWound to Report First Quarter 2023 Financial Results
12 mai 2023 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...